These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7827371)

  • 1. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis.
    Yamane K
    Intern Med; 1994 Oct; 33(10):579-82. PubMed ID: 7827371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
    Knock GA; Terenghi G; Bunker CB; Bull HA; Dowd PM; Polak JM
    J Invest Dermatol; 1993 Jul; 101(1):73-8. PubMed ID: 8331298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
    Vancheeswaran R; Magoulas T; Efrat G; Wheeler-Jones C; Olsen I; Penny R; Black CM
    J Rheumatol; 1994 Oct; 21(10):1838-44. PubMed ID: 7837147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's phenomenon and vascular disease in scleroderma.
    Kahaleh MB
    Curr Opin Rheumatol; 1994 Nov; 6(6):621-7. PubMed ID: 7865384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raynaud's phenomenon and vascular disease in systemic sclerosis.
    Generini S; Matucci Cerinic M
    Adv Exp Med Biol; 1999; 455():93-100. PubMed ID: 10599328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the diagnosis and management of scleroderma-related vascular complications.
    Kerin K; Yost JH
    Compr Ther; 1998; 24(11-12):574-81. PubMed ID: 9847974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma endothelin levels in systemic sclerosis.
    Kadono T; Kikuchi K; Sato S; Soma Y; Tamaki K; Takehara K
    Arch Dermatol Res; 1995; 287(5):439-42. PubMed ID: 7625853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pathogenic role for endothelin in Raynaud's phenomenon?
    Bottomley W; Goodfield M
    Acta Derm Venereol; 1994 Nov; 74(6):433-4. PubMed ID: 7701873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Narrow-sense' and 'broad-sense' vascular abnormalities of systemic sclerosis.
    Jinnin M
    Immunol Med; 2020 Sep; 43(3):107-114. PubMed ID: 32324110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification and pathogenesis of scleroderma.
    Winkelmann RK
    Mayo Clin Proc; 1971 Feb; 46(2):83-91. PubMed ID: 4925984
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
    Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
    Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.